Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome

Jérôme Harambat1, Astrid Godron, Sandrine Ernould

  • 1Service de Pédiatrie, Centre de référence Maladies Rénales Rares du Sud Ouest, Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France. jerome.harambat@chu-bordeaux.fr

Insights

Identifying children needing steroid-sparing agents (SSA) for idiopathic nephrotic syndrome (INS) is crucial. Achieving first remission quickly predicts the need for SSA in pediatric INS patients.

Area of Science:

  • Pediatric Nephrology
  • Immunology
  • Clinical Trial Design

Background:

  • Steroid-sensitive idiopathic nephrotic syndrome (INS) affects many children, with about half developing steroid dependency.
  • Prolonged steroid treatment carries adverse effects, necessitating early identification of high-risk patients for steroid-sparing agents (SSA).

Purpose of the Study:

  • To identify predictors for the requirement of SSA in children with steroid-sensitive INS.
  • To develop a predictive model for tailoring therapeutic strategies in pediatric INS.

Main Methods:

  • Retrospective hospital-based cohort study including children with steroid-responsive INS.
  • Follow-up duration of at least 4.5 months.
  • Cox regression modeling and decision curve analysis were employed.

Main Results:

  • Out of 120 children, 72 (60%) required SSA after a median of 10 months.
  • Male sex, age at onset, methylprednisolone pulse use, and time to first remission were significant predictors.
  • Time to achieve first remission was a strong independent predictor (HR=1.9 as continuous, HR=4.1 when dichotomized at 9 days).

Conclusions:

  • Time to first remission is a key predictor for SSA necessity in pediatric INS.
  • The developed predictive model demonstrated strong performance (AUC 0.81) and outperformed other strategies.
  • Further prospective studies are recommended to validate the prediction model's accuracy and clinical utility.
Abstract

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...